The FDA also approved the Vysis ALK Break-Apart FISH Probe Kit (Abbott) as a companion diagnostic test for the diagnosis of the ALK gene in patients with NSCLC to identify appropriate candidates for crizotinib therapy. The test uses fluorescence in situ hybridization to detect those rearrangements on the 2p23 chromosome. (August 26, 2011)
